AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2016
Jun 9, 2016
31801_dirs_2016-06-09_db4c8397-e8eb-4a44-bc71-0bf07f9660b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-06-08
Reporting Person: Wright Richard M. (Sr. VP & CCO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-06-08 | Incentive Stock Option | $4.72 | A | 75000 | Acquired | 2026-06-08 | Common Stock (75000) | Direct |
Footnotes
F1: 25% vest on June 8, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26